Home > Insider Trading > Filing (0001567619-18-001755)

Filing Details

Accession Number:: 0001567619-18-001755
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-08-23 18:03:08
Reporting Period:: 2018-08-21

Accepted Time:: 2018-08-23 18:03:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1740689	Michael Lane	C/O Idexx Laboratories, Inc. One Idexx Drive Westbrook ME 04092	Corporate Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-08-21	2,112	$62.00	5,519	No	4	M	Direct
Common Stock	Acquisiton	2018-08-21	2,226	$79.54	7,745	No	4	M	Direct
Common Stock	Acquisiton	2018-08-21	1,500	$67.85	9,245	No	4	M	Direct
Common Stock	Disposition	2018-08-21	5,838	$243.78	3,407	No	4	S	Direct
Common Stock	Disposition	2018-08-21	74	$243.75	3,333	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2018-08-21	2,112	$0.00	2,112	$62.00
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2018-08-21	2,226	$0.00	2,226	$79.54
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2018-08-21	1,500	$0.00	1,500	$67.85

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2024-02-13	No	4	M	Direct
136	2025-02-13	No	4	M	Direct
9,249	2026-02-13	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	592	Indirect	by spouse

Footnotes

Includes 598 shares held in the reporting person's IRA account and 23 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2018.
Represents the weighted average sales price of the shares sold ranging from a low of $243.75 to a high of $244.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.
Grant of option to buy 1,056 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Grant of option to buy 1,181 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Grant of option to buy 10,749 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2017.
Not applicable.